Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speaker : Prof. Jessica Lin

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

How 7,000 steps a day could help reduce your risk of cancer

Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Study finds that AI is better at forecasting the risk of developing cancer.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

Recommended Articles For You

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals 

How EPCORITAMAB is Revolutionizing the Treatment of Cancer 

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer 

Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New guidelines for radiation therapy for HPV-associated head and neck cancer

2.

Review looks at potential treatment targets in the tumor microenvironment.

3.

Even when they are not paying attention, children are still learning.

4.

The Benefits of Exercise for Substance Use Disorders.

5.

The top three drugs for multiple myeloma treatment upfront are four.

1.

The New Era of Oncology: Key Updates and Clinical Insights

2.

Everything You Need to Know About RDW-CV: A Comprehensive Guide 

3.

Decoding Granular Cell Tumor: What You Need to Know

4.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

5.

HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

3.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

Navigating the Complexities of Ph Negative ALL - Part XI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot